{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boucher G"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","Crohn's & Colitis Foundation of America","Canada Foundation for Innovation","Canada Research Chairs"],"pagination":["9-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8730700"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["<h4>Background</h4>Crohn's disease (CD) can affect any segment of the digestive tract but is most often localized in the ileal, ileocolonic, and colorectal regions of the intestines. It is believed that the chronic inflammation in CD is a result of an imbalance between the epithelial barrier, the immune system, and the intestinal microbiota. The aim of the study was to identify circulating markers associated with CD and/or disease location in CD patients.<h4>Methods</h4>We tested 49 cytokines, chemokines, and growth factors in serum samples from 300 patients with CD and 300 controls. After quality control, analyte levels were tested for association with CD and disease location.<h4>Results</h4>We identified 13 analytes that were higher in CD patients relative to healthy controls and that re"],"journal":["Inflammatory bowel diseases"],"pubmed_title":["Serum Analyte Profiles Associated With Crohn's Disease and Disease Location."],"pmcid":["PMC8730700"],"funding_grant_id":["U01 DK062420","U01 DK062431","U24 DK062429","R01 DK123530","DK062429","U01 DK062423","DK062423","DK062413","U01 DK062413","20415","U01 DK062432","U01 DK062422","202695","DK062420","DK062431","DK062432","DK062422","U01 DK062429","422348","230625","P30 DK043351","218944"],"pubmed_authors":["Schumm LP","Borowski K","Giri M","Chabot-Roy G","Vachon L","Hao K","Datta L","Hillhouse EE","Raquel M","Simpson CL","Chen W","Schwartz MB","Duerr RH","Charron G","Goyette P","Silverberg MS","Li D","Landers C","Ivinson S","Levings MK","Forest A","Botwin G","Johnston E","McGovern D","Sabic K","Kohen R","Bajpai M","Konnikova L","Birch S","Haritunians T","Cote-Daigneault J","Lazarev M","Daly MJ","Merad M","Levings M","Miladinova V","Proksell S","Lesage S","NIDDK IBD Genetics Consortium","Thompson-Legault J","McGovern DPB","White-Guay B","Itan Y","Duerr R","Cho J","iGenoMed Consortium","Cho JH","Sands B","Lachaine J","Fleshner P","Paradis A","Nayeri S","Bitton A","Stempak JM","Mengesha E","Targan SR","Coderre L","Cordero R","Filice M","Xavier R","Joseph L","Des Rosiers C","Brant SR","Rymaszewski K","Stevens C","Boucher G","Veilleux S","Gettler K","Rioux JD"],"additional_accession":[]},"is_claimable":false,"name":"Serum Analyte Profiles Associated With Crohn's Disease and Disease Location.","description":"<h4>Background</h4>Crohn's disease (CD) can affect any segment of the digestive tract but is most often localized in the ileal, ileocolonic, and colorectal regions of the intestines. It is believed that the chronic inflammation in CD is a result of an imbalance between the epithelial barrier, the immune system, and the intestinal microbiota. The aim of the study was to identify circulating markers associated with CD and/or disease location in CD patients.<h4>Methods</h4>We tested 49 cytokines, chemokines, and growth factors in serum samples from 300 patients with CD and 300 controls. After quality control, analyte levels were tested for association with CD and disease location.<h4>Results</h4>We identified 13 analytes that were higher in CD patients relative to healthy controls and that re","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T07:48:00.716Z","creation":"2025-04-04T07:48:00.716Z"},"accession":"S-EPMC8730700","cross_references":{"pubmed":["34106269"],"doi":["10.1093/ibd/izab123"]}}